Translate this page to:
In JoVE (1)
- Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT)
Other Publications (3)
Articles by Abass Alavi in JoVE
Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT)
Nehal N. Mehta1, Drew A. Torigian2, Joel M. Gelfand3, Babak Saboury2, Abass Alavi2
1Division of Cardiovascular Medicine, University of Pennsylvania, Perelman School of Medicine, 2Department of Radiology, University of Pennsylvania, Perelman School of Medicine, 3Department of Dermatology, University of Pennsylvania, Perelman School of Medicine
There is great need to identify atherosclerosis non-invasively, and here we demonstrate how FDG-PET/CT can be used to detect and quantify atherosclerotic plaque activity and vascular inflammation.
Other articles by Abass Alavi on PubMed
Differences in [99mTc]TRODAT-1 SPECT Binding to Dopamine Transporters in Patients with Multiple System Atrophy and Parkinson's Disease
European Journal of Nuclear Medicine and Molecular Imaging. Mar, 2005 | Pubmed ID: 15791439
Multiple system atrophy (MSA), a disorder causing autonomic dysfunction, parkinsonism, and cerebellar dysfunction, is difficult to differentiate from other movement disorders, particularly early in the course of disease. This study evaluated whether [99mTc]TRODAT-1 binding to the dopamine transporter differentiates MSA from other movement disorders.
Multimodality Optical Imaging and 18F-FDG Uptake in Wild-type P53-containing and P53-null Human Colon Tumor Xenografts
Cancer Biology & Therapy. Oct, 2007 | Pubmed ID: 17932466
During tumor development a switch to glycolytic metabolism known as the Warburg effect may provide cancer cells with a survival advantage and may also provide a therapeutic opportunity. A number of signals contribute to aerobic glycolysis including those mediated by HIF-1, c-Myc, Akt and Hexokinase. Recent studies have implicated the p53 tumor suppressor as a negative regulator of this switch. Using inducible p53 gene silencing in bioluminescent tumor xenografts we initially observed qualitatively similar levels of FDG uptake by PET small animal imaging in wild-type p53-expressing tumor xenografts and p53 gene-silenced xenografts. We further evaluated glucose uptake using FDG-PET/CT fusion imaging of green and red fluorescently-labeled wild-type and p53-null human colon tumor xenografts. Our results demonstrate that the wild-type p53-expressing tumor xenografts exhibit high levels of glucose uptake, similar to those observed in p53-null tumor xenografts, by quantitative PET imaging indicative of the glycolytic switch. Thus p53 function is not sufficient to suppress glucose uptake in cells and tumors that could theoretically support aerobic glycolysis.
18F-FDG Uptake in Lung, Breast, and Colon Cancers: Molecular Biology Correlates and Disease Characterization
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. Nov, 2009 | Pubmed ID: 19837767
It is hoped that in the not too distant future, noninvasive imaging-based molecular interrogation and characterization of tumors can improve our fundamental understanding of the dynamic biologic behavior of cancer. For example, the new dimension of diagnostic information that is provided by (18)F-FDG PET has led to improved clinical decision making and management changes in a substantial number of patients with cancer. In this context, the aim of this review is to bring together and summarize the current data on the correlation between the underlying molecular biology and the clinical observations of tumor (18)F-FDG accumulation in 3 major human cancers: lung, breast, and colon.